antigen receptor“). Tato terapie se používá asi 6 let ke zvládání B buněčných malignit a v poslední době je testována i u řady autoimunitních chorob. U myastenie jde o tři studie. Jedna studie zahrnuje upravené T buňky namířené proti maturačnímu antigenu B buněk (BCMA), (fáze II, NCT04146051), druhá potom proti MuSK protilátce (fáze I, NCT05451212) a poslední, která je také teprve ve fázi I (NCT05828225) pracuje s CD19 CAR T buňkami.

Od roku 2017, kdy byly publikovány výsledky studie REGAIN, došlo nejen k vývoji dalších účinných léků, ale i k významnému rozvoji poznání mnoha aspektů této závažné choroby. Vývoj nových léků tak stimuluje zpřesňování a prohlubování informací např. z oblasti patofyziologie, klinimetrie či epidemiologie. Je ovšem otázkou, kdy a v jakém rozsahu se tyto nové léky dostanou k pacientům.

LITERATURA

1. Bril V, Drużdż A, Grosskreutz J, et al. Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study. *Lancet Neurol.* 2023;22:383-394.
2. De Bleecker JL, Remiche G, Alonso-Jiménez A, et al. Recommendations for the management of myasthenia gravis in Belgium. Acta Neurol. *Belg.* 2024;124:1371-1383.
3. Dewilde S, Phillips G, Paci S, et al. People Diagnosed with Myasthenia Gravis have Lower health-related quality of life and Need More Medical and Caregiver Help in Comparison to the General Population: Analysis of Two Observational Studies. Adv. *Ther.* 2023;40:4377-4394.
4. Farmakidis C, Pasnoor M, Dimachkie MM, Barohn RJ. Treatment of Myasthenia Gravis. *Neurol. Clin.* 2018;36:311-337.
5. Gilhus NE. Treatment considerations in myasthenia gravis for the pregnant patient. Expert Rev. *Neurother.* 2023;23:169-177.
6. Gilhus NE, Andersen H, Andersen LK, et al. Generalized myasthenia gravis with acetylcholine receptor antibodies: A guidance for treatment. *Eur. J. Neurol.* 2024;31:e16229.
7. Habib AA, Zhao C, Aban I, et al. Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial. *Lancet Neurol.* 2025;24:117-127.
8. Howard JF, Bresch S, Genge A, et al. Safety and efficacy of zilucoplan in patients with generalised myasthenia gravis (RAISE): a randomised, double-blind, placebo-controlled, phase 3 study. *Lancet Neurol.* 2023;22:395-406.
9. Howard JF, Bril V, Vu T, et al. Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet Neurol.* 2021;20:526-536.
10. Howard JF, Utsugisawa K, Benatar M, et al. Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. *Lancet Neurol.* 2017;16:976-986.
11. Mahic M, Bozorg A, Rudnik J, Zaremba P, Scowcroft A. Treatment patterns in myasthenia gravis: A United States health claims analysis. *Muscle Nerve.* 2023;67:297-305.
12. Mantegazza R, Vanoli F, Frangiamore R, Cavalcante P. Complement Inhibition for the Treatment of Myasthenia Gravis. *ImmunoTargets Ther.* 2020;9:317–331.
13. Mevius A, Jöres L, Biskup J, et al. Epidemiology and treatment of myasthenia gravis: a retrospective study using a large insurance claims dataset in Germany. Neuromuscul. Disord. *NMD.* 2023;33:324–333.
14. Nair SS, Jacob S. Novel Immunotherapies for Myasthenia Gravis. *ImmunoTargets Ther.* 2023;12:25-45.
15. Nowak RJ, Coffey CS, Goldstein JM, et al. Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis: The BeatMG Study. *Neurology.* 2022;98:e376-e389.
16. Pane C, Di Stefano V, Cuomo N, et al. A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. *J. Neurol.* 2024;271:6209-6219.
17. Piehl F, Eriksson-Dufva A, Budzianowska A, et al. Efficacy and Safety of Rituximab for New-Onset Generalized Myasthenia Gravis: The RINOMAX Randomized Clinical Trial. *JAMA Neurol.* 2022;79:1105-1112.
18. Polák P, Penka M, Smejkal P, et al. Treatment with rituximab as an opportunity for the prevention of infectious complications. *Vnitř Lék.* 2016;62:398-405.
19. Saccà F, Pane C, Espinosa PE, et al. Efficacy of innovative therapies in myasthenia gravis: A systematic review, meta-analysis and network meta-analysis. *Eur. J. Neurol.* 2023.
20. Vu T, Meisel A, Mantegazza R, et al. Terminal Complement Inhibitor Ravulizumab in Generalized Myasthenia Gravis. *NEJM Evid.* 2022; 1: EVIDoa2100066.
21. Wiendl H, Abicht A, Chan A, et al. Guideline for the management of myasthenic syndromes. Ther. Adv. Neurol. *Disord.* 2023;16:17562864231213240.
22. Wolfe GI, Kaminski HJ, Aban IB, et al. Randomized Trial of Thymectomy in Myasthenia Gravis. *N. Engl. J. Med.* 2016;375:511-522.

